VeriSIM Life closes $15M series A round to advance AI-enabled drug research

Debiopharm announced a new investment in the San Francisco based start-up, VeriSIM Life, supporting the expanded application of their artificial-intelligence based computational platform BIOiSIMTM  that reduces the need for animal testing by narrowing down the number of compounds most likely to cure a disease prior to clinical research.

The financing round led by Morpheus Ventures, with Debiopharm Innovation Fund joining new investors including Colorcon Ventures along with existing investors OCA Ventures, Intel Capital, Serra Ventures and Susa Ventures. Debiopharm’s co-investment in VeriSIM Life will facilitate the expansion of transformational partnerships with industry and academia using BIOiSIMTM, their first-in-class ‘virtual drug development engine’.

Click here to access their full press release